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ABSTRACT

The Synthesis of Various Substituted
3-Amino-7-hydroxy-2,2-dimethyltetralins
and Their Opioid-related Activities
David Alan Lippman

A series of aminotetralones and aminotetralins were synthesized
from the common intermediate F, 3-amino-2,2-dimethyl-7-methoxy1-tetralone.

The final compounds derived from F were simple substituted

and/or reduced analogues.

The products would allow a progressive

structure activity relationship to be drawn based on pharmacological
testing.
The common intermediate F was synthesized utilizing a six step
procedure starting with p-raethoxyphenylacetic acid.
from the precursor to the F:HC1 was 25%.

The overall yield

Compound F was either

O-demethylated to form 3-amino-2,2-dimethyl-7-hydroxy-l-tetralone (I) or
was dimethylated on the amine and subsequently O-demethylated to yield
the 3-dimethylamino-7-hydroxy-2,2-dimethyl-l-tetralone (J).

The last

major modification was the reduction of the carbonyl group in J to a
methylene, to produce the 3-dimethylamino-7-hydroxy-2,2~dimethyltetralin (L).

These final compounds I, J, and L, as well as the

intermediates leading to them (compounds F, II, G, and K), were tested
for opioid activity in the isolated guinea pig ileum assay as described
by Kosterlitz.
ili

All of the compounds exhibited agonist activity. They generally
fell into three groups.

Compound J was the most potent, giving 1/40 the

potency of normorphine (NM).

The majority of compounds (F, H, K, and L)

were of intermediate potency, ranging in activity from 1/500 to 1/700
the potency of NM. The last two compounds I and G were not only the
least potent at 1/2000 to 1/5000 that of NM, but also the least
efficacious.

In evaluation of the receptor selectivity of the compounds

synthesized, a range of selectivity was observed.

Compound J was the

only compound which appeared to exhibit 100% of its activity through the
mu receptor.

The other compounds had varying degrees of mixed receptor

agonism.
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INTRODUCTION

In medicinal chemistry, one oust have a suitable lead compound
which may be varied or dissected structurally to upgrade potency and
eliminate unwanted side effects.

Morphine (Structure I) offered the

best point of departure in the search for a potent analgetic agent *nh
little or no addiction liability.

Structure I

Pharmacological Basis

Literature reports on the use of opium can be traced to the
beginnings of recorded medical history and its use may extend veil oxer
2000 years.

The isolation of the principal active ingredient from the

opium poppy, Panaver sominiferum. was in 1805 by Sertutner (.). f.ll«d
f ,„HPine
in 1832 by the isolation of codeine.

1

More than a century elapsed before

2

Gulland & Robinson (2) determined the structure of morphine in 1925
(Structure I).

Gates & Tschudi confirmed the structure of morphine by

completing its total synthesis in 1952 (3),
stereochemistry quickly followed (A).

Assignment of the absolute

In 1898, which was 25 years prior

to the identification of the chemical structure of morphine, the
synthetic modification was worked out to produce heroin (the diacetyl
derivative).

During the next 25 years hydroxycodeinone and dihydro-

hydroxycodeinone (5) were prepared and are still in use today.

Structure Activity Relationships
The first structure activity relationship (SAR) studies of opioids
were initiated in 1929.

This early work led to the synthesis of

approximately 150 morphine derivatives and over 300 semi-synthetic
products (for a review see Ref. 6).

This was the foundation for future

synthetics and semi—synthetics such as metapon (7) (5-methyldihydromorphine), oxycodone and oxymorphone (8).
The general SARs for Structure II are described as follows:

With

Rj = -H, R2 = -CH3 and a double bond between C-7 and C-8, substitution
of an alpha-OH, beta-OH, =0, -OCH3 or halogen (i.e., -01) at C-6, or
moving the double bond to C—6 and C—7, all generally increase activity
and toxicity.
With a double bond between C-6 and C-7 (in the C-Ring) substitution
0f

-OH at C-8 causes a decrease in activity, yet a -CI at C-8 promotes

increased activity.

With no unsaturated bonds in the C-ring, a general

increase in activity is seen.
tfill

Additional substitution of an -OH at C-14

further increase activity.

Modifications of the C-ring generally

-R|

Structure II

produce quantitative changes* this being an increase in potency
proportional to an increase in side effects.

Metopon and azidomorphine

are possible exceptions, where there is an increase in activity and a
decrease in side effects.

An intact A-ring is essential for agonist

activity, and if Rj is alkyl instead of —H (as in morphine), e.g., -CH3
or -CH2-CH3, potency is decreased. Further substitution of the A-ring
will decrease activity.

A notable exception is acetylation (Rj = -COCH3

and substitution of an -OCOCH3 at C-6) which results in increased
potency (i.e., heroine).
The nitrogen substituents (R2) confer some quantitative changes in
activity but more significant qualitative changes such as agonist* mixed
agonist-antagonist, or pure antagonist activity.
substitutions of —CH3 or —CH2—CH2~^6^5
being the more potent.

ai*e

For example, R2

agonists with the phenethyl

When R2 = -CH2-CH=CH2, Ri =

and

-OH is

4

substituted at C-6, as well as a double bond existing between C-7 and
C-8, the resultant compound is nalorphine which displays mixed
agonist-antagonist activity.

Pure antagonism is conferred by retaining

f?2 as -CH2~CH=CH2 and introducing a keto at C-6 and hydroxy at C-14 as
in naloxone.

A significant increase in potency is obtained if the allyl

group on the amine is replaced by a -CH2~<^^ , this being the case for
naltrexone.
It was in 1915 that Pohl (9) observed the reversal of morphine's
respiratory depressant effects by the administration of the N-allyl
derivative of norcodeine.

In the early 1940's N-allylnormorphine

(nalorphine) was shown to have antagonist activity.

The uniqueness of

nalorphine's pharmacology was not truly appreciated until Lasagna &
Beecher (10) discovered in 1954 that it possessed potent analgetic
activity in humans, and in addition is able to completely block
morphine's effects.

This raised the dichotomy of why in animal testing

(such as the hot plate and tail flick assays) only antagonist activity
was seen, but in man analgetic activity was significant.
In pursuing the synthetic route initiated by Grewe in 1946 (U),
Schnider & Grussner (12) discovered that the furan (ether linkage) ring
of morphine (Structure I) could be eliminated and yet the molecule would
still retain potent analgetic activity.

The morphmans (Structure III)

are compounds that are structurally related to morphine but lack the
4,5-epoxy bridge.

The

N-methylmorphinan which was originally sy

sized was evaluated to have only 20% of the analgetic potency o
i
i\
morphine, but its levo isomer (levorphan )

later found to exhibit

5

four times the potency of morphine, and is the prototype of this drug
class (13).

R^-N\s

14

Structure III

Potent agonists can be created with an R2 substituent of phenethyl
or p—aminophenethyl; however, this drug class was of greater interest
because of its potential to yield mixed agonist—antagonist compounds.
With a phenolic group on what is analogous to the A-ring of morphine, a
zhange of the R2 substituent on the amine from -CH2~CH=CH2 (which is a
strong antagonist) to a -CH2-<^J group causes a change in. activity to a
strong agonist with antagonist effects.
3ble to produce hallucinations.
:o

-<^j and Rj

the R2 = -CH2

In addition this compound is

If an -OH at C-14 is added in addition

= -H, the resultant compound has strong

mtagonist and weak agonist effects.

Substitution of R2 with

:auses the molecule to become a strong agonist with weak antagonist
;ffects.

In 1955 further simplification of the morphine backbone came about
with the removal of the "C" ring by May & Murphy (14) which produced the
benzomorphans or benzazocines (Structure IV).

In doing so the first

analgetic to show a separation between analgesia and addiction potential
was created. The prototypal agent (Rj = -H, R2 = -CH2CH2C5H5, R3»R4 -

-CH3) phenazocine was the first compound of this class to be studied
extensively.

R

Structure IV

The SARs for the benzomorphans are generally as follows: a phenolic
substituent at the 2'-position (Rj = -OH) usually affords greater
activity than hydrogen.

Any other substituent at the 2'-position (e.g.,

NH2, NO2, F, CI) (15) has shown less.potency than the previous two.

An

R3 replacement of a beta-OH decreases the agonist activity but will
increase the antagonist activity. If R4 is substituted with a -C5H5,
potent analgesia is seen.

With R3 a beta-CH3» and Rj ™ -OH, the

resultant drug is equipotent to morphine but precipitates withdrawal

7

effects in morphine-dependent monkeys.

Keeping Rj - -H* a substitution

of R2, R3 and R4 = -CH3 will show a threefold increase in potency over
^2* ^4 = -CH3 and R3 =» -H.

As in the previous discussion of opioids,

the R2 substitution of a phenethyl group( -CH2-CH2-C6H5) conveys a
20-fold gain in analgetic potency over a small aliphatic group (i.e.,
-CH3).

It has been shown that some benzomorphans with R2 • -£^3 in

combination with a large substituent at R3 do display antagonist
properties (16).
Serendipity took a hand in one significant advance of analgetics
when Eisleb & Schaumann (17) synthesized meperidine in 1934. This
compound was originally proposed to be an antispasmodic.

In addition to

its antispasmotic effect, meperidine was pharmacologically seen to cause
straub tail in rats, which is indicative of an analgetic.

The activity

was about 20% that of morphine, but of far greater importance was the
discovery of an active analgetic that did not closely adhere to the
phenanthrene structure of morphine.

Based on this new information,

thousands of phenylpiperidine derivatives have since been made.

Some of

these derivatives exhibited extraordinary potency [carfentanil is nearly
18,000 times more potent than meperidine (18)] and a few of them have
seen clinical use.

The year 1940 brought about a radical simplification

in the structure of analgetics with the synthesis of methadone, in which
the nitrogen atom is in a totally acyclic arrangement (19).
In the late 1960's and early 1970's, Martin et al. (20, 21 and
references cited therein) reported active analgetic compounds which were
aminotetralln (Structure V) derivatives.

The commonly accepted

8

structural components necessary for analgetic activity are retained in
the arainotetralin structure.

These features are the aromatic ring, the

quaternary C-l substitutions, the amine separated from C-l by a two
carbon linkage, and the tertiary amine.
Martin e.t al. (22, 23) prepared compounds where the aromatic ring
was left unsubstituted, or where it had a methoxy or hydroxy group in
the 7 position (as per the numbering in Structure V).

Structure V

The most interesting compounds of the aminotetralin series contained
3-dimethylamino-l-phenyl substituents. The activities of the cis and
trans diastereomers of the compound were reported from the mouse hot
plate assay (23).

When there is no substitution at the 7-position (R =

-H), the two isomers are about equipotent and equal in activity to
meperidine.

When R = -OH, the activity of the trans isomer increased

about 50% and that of the cis isomer increased by about 25%.

This

change in activity is consistent with the observation that the intro
duction of an -OH group at this position causes an increase in analgetic
activity.

9

Interestingly, both isomers where R «* -OCH3 were less active than
the corresponding compounds which were unsubstituted at this position.
This pattern of structure activity relationships does not hold in all
the aminotetralins.

In the series with 3-diraethylamino and 1,1-dimethyl

substitutions, the order of potency for C-7 substituents is R * -H > R *
-OCH3 _> R — -OH (20).

The compound in which R = -H was reported to be

2.5 times as potent as meperidine is the most potent of the aminotetralin
series to date.
In 1981 Fries & Bertelli (24) synthesized a series of amino
tetralins lacking the phenolic hydroxyl and the quaternary C-l carbon.
Their results suggested that the conformation about the C-l position was
not a critical factor for. activity, although elimination about the C-l C—2 carbons, resulting in a double bond and a more planar compound,
caused an eradication of agonist activity when judged by the hot plate
assay..

The determination of the importance of this observation will

require further investigation.
These 3-(cyclopropyTmethyl)methylamino-l-phenyltetralins displayed
significant agonist and antagonist activity.

The fact that in prelimi

nary studies in morphine-addicted monkeys the trans isomer did not
precipitate withdrawals, nor did it suppress the abstinence syndrome, is
indicative of a non—mu receptor type activity.

Receptors
The findings of Goldstein et al. (25) in 1971, which fathered the
idea of specific brain opioid receptors, were confirmed two years later
by two groups [those of Pert and Snyder (26), and Simon et al. (27)], who

10

explored the pharmacological repercussions of receptor occupancy.
Several groups of investigators then pursued the search for an
endogenous ligand, because such a ligand seemed to be a much more
sensible receptor occupant than an exogenous alkaloid and because the
specific distribution of opioid receptors resembled the anatomy of known
pain pathways.
Although Beckett & Casey (28) and Portoghese (29) had speculated on
the nature of the opioid receptor, in 1977 Kosterlitz et al» (30)
furthered their work by postulating that the receptor was stereospecific
and possessed a high affinity for endogenous opioids.

Two criteria were

set in order to establish the fact that neuronal responses to opioids
involve stereospecific opioid binding sites. The first was that naloxone
(an antagonist) could block the effects of the agonist.
criterion was the ability to display stereo-selectivity.

The second
Thus, the

levorotatory enantiomers of most agonists mimic the actions of the
endogenous ligands while the dextrorotatory enantiomers do not exhibit
similar effects at the same dose (concentration).

Subsequent studies

elucidated the fact that brain preparations showed a saturable,
stereospecific binding site with high affinity for opioid agonists and
antagonists (31).
Martin addressed the dichotomous nature of nalorphine from results
of his own studies, in addition to those of many others (32-35).

He

first postulated that receptor dualism (35) was conceptually defined
through the presence of multiple receptors or receptor redundancy,
light of observations from further research (36, 37), the conclusion

11

that two receptors existed established the presence of the M-receptor
(for morphine) and the N-receptor (for nalorphine).

In studies with

chronic spinal dogs (39-41), three clearly distinguishable syndromes
from single dose injections of morphine, ketocyclazocine, and N-allylnormetazocine (SKF-10,047) were seen. Cross tolerance effects (i.e.,
whether these drugs were able to precipitate or suppress the withdrawal
syndrome to one another) helped formulate the basic idea of the "three
opioid receptors."

Establishing the validity of several opioid receptor

types provided a reasonable explanation for the observations of
different pharmacological actions of analgetic compounds by their being
either agonists, mixed agonist-antagonists, or antagonists (42).
The three specific receptors suggested by Martin (43) to mediate
the effects of opioids were named for the prototypic drugs which
produced distinct effects in laboratory dogs.

The receptors were named

mu., for morphine, kappa, for ketocyclazocine, and sigma, for SKF-10,047
(N-allylnormetazocine).
In 1977 while investigating opioid peptides and their binding
characteristics in in vitro assays, the research group of Lord,
Waterfield, Hughes and Kosterlitz concluded that the receptor population
of the guinea pig ileum and mouse vas deferens (MVD) were not identical.
The receptor in the MVD where the enkephalins and endorphins were mainly
exerting their activity was named the delta receptor (44).
Receat reports have shown that the mu and delta receptors mediate
significant effects on respiration.
for their addiction liability.

Most mu agonists to date are noted

It is proposed that sigma receptors may

12

have a significant role in psychotic behavior.

In addition, many kappa

agonists promote some psychotic behaviors, which are believed to be
mediated through the sigraa receptors. The delta, kappa and mu type
receptors are proposed to be the analgetic mediating receptors, and as
such would be the ideal receptors to optimally stimulate, if one is
seeking analgetic agents.

Of these receptor types, if specific stimu

lation were possible, the kappa receptor would be preferable.
The importance of knowledge about individual opioid receptors is
that by delineating the physiological function of each receptor type and
the selectivity of individual analgetics to bind to these receptors,
more selective and ideally more potent analgetics may be designed.
Endogenous opioids are peptides that are synthesized in the body
and elicit responses similar to the morphine-like analgetics.

The first

endogenous opioids discovered, methionine and leucine enkephalin (Fig. 1),
were separated from brain homogenates (45). They have since been found
in other sites such as the gut, adrenal medulla and autonomic nervous
system.

Beta endorphin (Fig. 1) was originally found in the pituitary

and has also been found in the hypothalmus (46).
The enkephalins and endorphins show some structural similarities
(amino acid repetition) to each other, in addition to the exogenous
analgetics (whose SARs have been studied extensively).
In a very broad evaluation, the endogenous opioids exhibit many of
the same effects as the exogenous opioid agonists, although the former
show minimal to nonexistent side effects.

The significantly potent

exogenous molecules generally are levorotatory isomers, although
exceptions do exist (47).

13

Tyr-Gly-Gly-Phe-Leu (leucine enkephalin)
Tyr-Gly-Gly-Phe-Met (methionine enkephalin)
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-ThrPro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-ValLys-Asn-Ala-His-Lys-Lys-Gly-Gln (Beta endorphin)

JQJ

HO

MHz
i

0^

Mr
H

Y

^Gly-Phe-Met

i

0

Figure 1.
Amino Acid Sequence of some endogenous opioids.
The boxed in region represents structural
similarities to opiates.
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The existence of endogenous opioid ligands has explained many facts
that often were attributed to being "wives* tales" or psychosomatic in
origin.
(48).

A most notable example has been placebo analgesia effects

It was shown that placebos could elicit some of their effects

through an opioid-mediated system which was reversed by a challenge of
naloxone.

The relief of pain by acupuncture was also reversed by a

naloxone challenge (49, 50).

It is interesting to note that hypnosis-

induced analgesia does not seem to be associated with opioid mediated
analgesia, since the naloxone challenge does not reverse the analgetic
effects that were induced (51).
The fact that certain forms of analgesia are not mediated by
opioids was discussed in the article by"Mayer (52) in which it was
mentioned that some types of pain may have dual modulation by both an
opioid and non-opioid system.

This duality would account for the

partial blockade of analgesia by naloxone.

It is important to find out

how the non-opiate system does work and to determine the mechanism of
cortical mediation for pain based solely on perception.
Opioid receptors and endogenous opioid peptides are found in many
parts of the body.

The most important sites for this part of the

discussion are the ones that are in the brain and spinal cord.

The

existence of endogenous opioids and a knowledge of how they inhibit pain
is of invaluable importance in the further understanding of analgetics.
Because of the considerable complexity of the opioid receptors a single
assay procedure cannot provide unequivocal results, especially with
peptides.

The mu and delta agonists have been shown to bind

15

preferentially (specifically) in the mouse vas deferens, but not in the
guinea pig ileum.

Mu receptors bind morphine with 10 times the affinity

of enkephalin, and conversely delta receptors exhibit approximately 100
times the binding affinities for enkephalins over morphine.

Naloxone's

affinity is 20-30 times greater for the mu receptor than for the delta
receptor (44).
In a recent research paper by Schmauss and Yaksh (52), preliminary
observations were made which suggested that a different opioid structure
activity relationship might exist for nociceptive stimuli of different
modalities.

They concluded that the populations of spinal opioid

receptors modulating the cutaneous thermal response possessed distin
guishable pharmacological characteristics which resembled those
described as mu & delta; whereas the visceral chemical responses were
modulated by spinal receptors with profiles having characteristics
resembling those of mu & kappa.

These observations were very important

for subsequent evaluation of stated conclusions documenting the agonistantagonist nature of analgetics, since misleading results may be drawn
.based on the screening procedure used and the desired evaluation of
results.

In addition, the partial agonists (pentazocine, buprenorphine,

nalorphine) can readily block visceral chemical pain but are considerably
less active on cutaneous thermal pain (54, 55).

Determinations of

receptor selectivity of pharmacological compounds (drugs) are made
through selective utilization of chemical tools, such as antagonists,
which were discovered a long time ago and are still used in order to
elucidate pharmacological actions of drugs.
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Narcotic Antagonists

Opioid antagonists are usually structurally similar to the agonists.
The exogenous or endogenous agonist exerts a positive effect (intrinsic
activity) upon binding to the receptor. The antagonist's effect is to
prevent the agonist's effect by occupying the receptor site itself or
mitigating the effects of the agonist via a different point of binding.
The result of the action of the antagonist is that the receptor fails to
tri8ger

its usual response to an agonist.

Blocking the effects of

exogenously applied opioids was not the only response that was seen with
analgetic antagonists, since pure antagonists also seemed to elicit some
effects on their own (when not given as a challenge to an exogenuous
drug).

It was deemed possible that the effects seen may have been due

to the presence of an endogenous compound which was subsequently
affected by the presence of the antagonist.

From that deduction and

work that was done in the late 1960's, it is now common knowledge that
there are endogenous opioids.

Antagonists play very important and

instrumental roles in the differentiation and characterization of
analgetics, their properties, expected effects and side effects, and how
each of the receptors in turn mediates specific responses in the body.
Because antagonists have the ability to inhibit responses of
agonists, certain disease states have been attributed to possible
imbalances of endogenous opioids and endogenous opioid receptors. The
use of opioid antagonists for disease states such as septic shock
(56-58), cardiogenic shock (56), and cerebral ischemia (59, 60) have
been documented.

Recently it has been shown that antagonists may have a

beneficial effect in the control of obesity in man (61).
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Physiological Basis
Pain
Some forms of physical discomfort may be described as painful.
No two persons perceive a painful stimulus in exactly the same way, and
each person describes pain somewhat differently.

Pain is perceived by

nociceptive nerve endings located in the skin, viscera and body walls,
and may be activated by thermal, chemical or mechanical stimuli. These
pain impulses are transmitted by primary afferent fibers (A delta and C
fibers) to the dorsal horn of the spinal cord (62), where complex
interactions occur.
The circuitry of the superficial dorsal horn is an area under active
investigation.

Studies have shown that primary afferents terminate on

both second-order sensory projection cells (63) (such as spinothalamic
tract cells) and intrinsic interneurons within the spinal column. There
is experimental evidence that some of the interneurons are excitatory
relay cells (64), whereas others are probably inhibitory or regulatory
interneurons (65).

There are numerous interneurons within this region

which contain enkephalin—like immunoreactivity and may have an inhibitory
function (66, 67).

Most of the secondary fibers cross at the anterior

white commisure and ascend via the spinothalamic tract to the thalamus
as part of the classical pain tract.
In addition to the classical spinothalamic tract, other spino tracts
such as the spinoreticular, the spinocervical and possibly the ventral
spinothalamic tracts may also be important in pain perception (63, 68)
While ascending to the thalamus, these tracts send collaterals to

18

areas of the brain stem concerned with nociception giving the potential
for much interaction, integration and reflex activity.
Areas of the brainstem, such as periventricular diencephlon and
periaqueductal gray, have been shown to contain opiate receptors and/or
to originate long decending monoaminoergic fibers (nucleus raphe magnus;
NRM) to the dorsal horn of the spinal cord (69).

These descending

pathways (raphe-spinal) synapse in an axo-axonic manner, possibly with
the primary afferent fiber and/or the inhibitory interneurons, and
thereby modulate pain information transmission from these fibers (69).
The simplest hypothesis is that these inhibitory interneurons are
activated by these descending medullospinal pathways (e.g., raphespinal).

Supporting this hypothesis is the evidence that naloxone

blocks the analgesia produced by electrical stimulation of the NRM and
partially blocks NRM—induced inhibition of dorsal horn cells (69).

This

system is one of the brain's pain-modulating mechanisms and links the
midbrain, medulla, and spinal cord.
Recent studies show the presence of mu and delta receptors on the
primary afferents (70).

The existence of these does not necessarily

indicate physiologically relevant receptors (71), yet the potential
sites for opioid action are indicated.

Kappa receptors on the primary

afferents have not yet been demonstrated, although Gouarders (72) has
demonstrated binding in the spinal cord.

Analgesia
Analgesia is a decrease in the perception of discomfort from pain,
although it is not always successful in the partial or complete
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eradication of that perception.

Ideally, analgetics should not cause

mental cloudiness or any other physical abnormality such as a decrease
in respiration rate or sedation. In long term use of high dose narcotic
analgetics8 patients usually tend to develop a tolerance to the negative
effects relative to the analgetic effects.

This is the case in the

clinical reports on the maintenance of the relief of the chronic and
intractable pain of cancer patients.
Although it is often said that analgetics cause respiratory
depression, mental confusion, and excitability in cancer patients, it
has been documented that the pain is able to balance these negative side
effects associated with short terra use of analgetics (73).

STATEMENT OF PROBLEM

The purpose of this research project was to delineate the
structure-activity relationships of the keto moiety and the amino
substituents in the aminotetralin analogues to opioid activity.

In

addition, the relative contribution to activity of the aromatic methoxy
or hydroxy group would also be evaluated.
To accomplish this, it was decided that the seven target compounds
in Table 1, represented by Structure VI, would be synthesized.
F had been synthesized previously.

Compound

The following discussion will

describe the approach taken for the synthesis of the compounds.
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Structure VI

Table I
Substituents of Aminotetralins

Compound

Rj

^2*^3

F

-OCH3

-H

=0

I

-OH

-H

=0

H

-OCH3

-CH3

=0

J

-OH

-CH3

=0

G

-OCH3

-H

-H,(-H)

K

-OCH3

~CH3

L

-OH

-CH3

-H,(-H)

SYNTHESIS OF THE COMPOUNDS

The synthesis of these compounds was to follow the procedures given
in a personal communication from Dr. P. Janssen relating to certain
9,9-dimethylbenzomorphans which he had previously reported (74). The
established synthetic procedures would be followed with few modifica
tions.

The proposed method, as briefly summarized in Scheme I, entailed

starting with para-methoxyphenyl-acetic acid, converting it into the
methyl ester (A) and by running a Reformatsky reaction on that ester, to
form the keto-ester (B).

This compound would then be reductively

aminated by treating it with benzylaraine in refluxing toluene and
azeotroping off the water to form the inline (C) which would then be
hydrogenated to give the free aminoester (D).

The amino ester would

then be heated with 50% aqueous KOH, thereby converting it to the
corresponding amino acid (E).

Once isolated, the amino acid would

cyellzed with polyphosphoric acid.

This reaction would produce

« y

intermediate compound F (3—amino-2,2-dimethyl—7-methoxy 1 tet
Compound F, which had been synthesized previously in the
laboratories of the Medicinal Chemistry Department of this university,
would be the common intermediate for this synthetic sequence (Sch
II).

Once obtained it would be converted to the HC1 salt.

This

compound would then be O-demethylated by use of BBr3, thus providi g
3-amino-7-hydroxy-2,2-dimethyl-l-tetralone (compound I).

Compound F

will also be converted into the dimethylamino substituted co.p
alkylating the amine with NaCNBH3 and H2CO.
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Compound H
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O-demethylated to give the phenolic (7-OH) compound J. The reduction of
the carbonyl group on compound F would give compound G, which is another
key intermediate for synthetic routes to be performed.

Compound G would

then be dimethylated to give compound K, (3-dimethylamino-2,2-dimethyltetralin), which in turn would be subsequently O-deraethylated to the
phenolic compound L.
The pharmacology would then be done on these compounds in an
isolated tissue preparation.

Evaluation of structure activity

relationships would then be made.

MATERIALS AND METHODS

Instrumentation
Melting points were done on a Hoover melting point apparatus in
open capillaries and are uncorrected.

The melting point of I:HBr was

done on a Kofler Micro Hot Stage melting point apparatus and is
uncorrected.
Infrared spectra were done either in AgCl cells (Wilks) or as the
KBr pellets prepared with the Carver press, and were run on a PerkinElmer model 283 continuous grating spectrophotometer.
shown on the individual spectral recordings.

Parameters are as

Nuclear magnetic resonance

(NMR) spectra were done on a Varian XL—200 spectrometer, in a 5 mm
broadband (switchable) probe, using an internal computer generated
reference based on the solvent protons.
individual spectra.

Parameters are shown with

The NMR spectrum of J was done on a Varian XL—400

spectrometer.
Mass specta were done at the National Institutes of Health (NIH),
Bethesda, MD.

Most were obtained by chemical ionization (CI) and were

done on a Finnigan 1015D.

Those done by electron ionization (EI)

methods were run on a Hitachi RMU-6E (70ev) and are noted as such.
Elemental analyses (C, H and N) were performed at the microanalytical laboratory of NIH.
All TLC plates were Merck F-254 (5760-2), 5 x 10 cm, silica layer
0.25 mm thick. Visualization, unless otherwise mentioned, was
accomplished by UV light.
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All solvents were of reagent grade quality unless otherwise noted.
The water was double distilled and run through a Nanopure^ system. The
tetrahydrofuran (THF) used in reactions was freshly distilled from a
solution of sodium and benzophenone.
Experimental
Methyl 4-Methoxyphenylacetate (A).

A solution of 150 g (0.90 mol)

of 4-methoxyphenyl-acetic acid (Aldrich Chemical Co.) in 1.0 L of
spectral grade MeOH (Eastman) was saturated with HC1 gas, then stoppered
with a drying tube and stirred for 72 hours.

The volume of solvent was

reduced on a rotory evaporator, the pH of the solution was adjusted to
6.0 with NH4OH and the remaining volatiles removed under vacuum. The oil
remaining was distilled to give 142.8 g (88% yield) of the ester A, bp 110°C at 0.250 mm Hg.
Ethyl 2,2-Dimethyl-3-keto-4-(p-methoxyphenyl)butyrate (B). Prior to
the reaction, reagent grade zinc granules were cleaned by treating them
with a 9:1 solution of concentrated H2S0£ and concentrated HN03> rinsing
thoroughly with distilled H20, and then acetone/H20.

The cleaned zinc

was dried by placing it in an oven and then stored in a vacuum
desiccator.
A mixture of 50 mL of THF, 22.7 g of Zn and 0.1 g of iodine were
combined in a 3000 mL flask under N2 and gently refluxed.

A solution of

76.1 g (0.39 mol) of ethyl 2-bromoisobutyrate, 54.0 g (0.39 mol) of the
methoxy ester A and 50 mL THF was added dropwise to the refluxing
reaction mixture at a rate to maintain turbidity, kithin 3 to 5 hours
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the starting materials had disappeared from the reaction mixture (TLC),
and the reaction was considered to be complete. The reaction mixture
was cooled and acidified to pH * 2—3 with 4N H2SO4 and the solvent
removed under vacuum.

Ester B was isolated by vacuum distillation which

gave 97.0 g (0.37 mol, 94% yield) with a bp = 145-155°C at 1.0 mm Hg.
Ethvl 3-Benzylimino-2,2-dimethyl-4-(p-methoxyphenvl)butvrate (C).
Into a 1 L flask fitted with a Dean Stark trap and a condenser with a
drying tube, 97.0 g (0.37 mol) of B were dissolved in 300 mL of
technical grade toluene.

A solution containing 41.0 g (0.38 mol)

benzylamine (Aldrich) and 0.75 mL boron triflouride etherate (Eastman)
in 50 mL toluene were added and the resultant mixture was refluxed.
After 16 hours, 6.5 mL of water had accumulated in the Dean Stark
trap.

An additional 19.0 g of benzylamine and 1.5 mL of 48% HBr in

glacial acetic acid were added, and the refluxing was continued.
3 hours the total water in the Stark trap was 13.0 mL.

After

The reaction

mixture was then cooled, washed with 10% NaHC03, and dried over MgS04.
The toluene was removed on the rotary evaporator and the crude product
was distilled at 145-155°C at 0.150 mm Hg, giving 95.6 g of compound C
as an oil (0.27 mol, 73% yield).
Ffhvl g-Amino—7-2

dimethyl-A

-fp—methoxvphenvl )butyrate ("l-

Int° 3

Parr bottle containing 150 mL of glacial acetic acid, 95.6 g (0.27 mol)
of C were dissolved and 0.5 g Pt02 added.

The solution was placed on

the Parr Hydrogenation apparatus at initial H2 pressure of

P

After 8 hours 1.0 g of 10% Pd/C was added and hydrogenation continued.
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After 96 hours, hydrogenation was stopped and the catalyst removed by
vacuum filtration.

The acetic acid volume was reduced to 1/5 its

original volume under vacuum.

The remaining solution, which was made

basic (pH=10) with 50% aqueous KOH, was then extracted twice with Et20
(75 mL) and then twice with CH2CI2 (75 mL)..

The combined extracts were

dried over MgSO^, filtered, and the solvent removed under vacuum.

Vacuum

distillation of the crude oil gave 50 g (0.19 mol, 70% yield) of amino
ester D, bp = 125-129°C at 0.025 mm Hg.
The free base D (50 g) was dissolved in 300 mL dry Et20, then HC1 gas
bubbled in until crystal formation ceased.

The solution was filtered,

and the crystals were then washed with Et20 and dried under vacuum. This
yielded 36.08 g (0.12 mol, 63% yield) of D:HC1^ rop = 136°C.
3-Amino-2,2-dimethy1-4-fp-methoxyphenyl)butyrate (E).

The 36.08 g

of D:HC1 were dissolved in 300 mL of distilled H2O, and 0.14 mol KOH
were added along with enough MeOH (approximately 50-75 mL) to keep the
amino ester in solution. The reaction solution was refluxed for
72 hours, then neutralized with concentrated HC1 to a pH of 7 and
concentrated.under vacuum.

The amino acid precipitated upon addition

of distilled water, and was isolated by filtration to give 25.63 g
(0.11 mol, 92% yield). The amino acid was recrystallized twice from
water to give 20.23 g of pure crystalline E, mp = 207-209°C.
3-Amino-7-roethoxy-2,2-dimethyl-l-tetralone (F).

A boiling water

bath was used to heat a bottle of polyphosphoric acid (PPA).

Once the

PPA had liquified sufficiently, 25 gra were placed in a round bottom
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flask and agitated using mechanical stirring.

The flask was replaced in

the water bath and the temperature monitored.

When the PPA had reached

lOO^C, 14.0 g of E (0.06 mol) were added slowly.
were continued for 2 hours.

Heating and stirring

The mixture was cooled by adding 500 g of

ice and 250 mL of H20. The resulting mixture was basified to pH »
10-10.5 with solid K0H and extracted with four 500 mL portions of CHCI3.
The combined extracts were evaporated under vacuum; the remaining oil
was distilled to give 9.9 g (0.045 mol, 76% yield) of amino tetralone F,
bp = 133-145°C at 0.10 ram Hg.
Anal.

C13H18N02C1 (M.W. = 219.29);

Calcd. C, 61.05; H, 7.09; N, 5.48;
Found

C, 60.76; H, 7.32; N, 5.65.

Mass spec CI M+l = 220.
See IR Fig. 2 and NMR Fig.. 3.
3-Dimethylamino-2,2-diraethyl-7-methoxy-l-tetralone (H).

A solution

of 3.0 g (13.68 mraol) of F and 4.04 g (78.5 mmol) of 90% formic acid
were mixed in a 50 mL flask at room temperature, then warmed gently at
35-40°C until clear.

To this solution 34.2 mmol (3.02 g) of 35%

formaldehyde were added dropwise, with continuous stirring.
A drying tube and condenser were attached to the reaction flask
and the solution was heated to 100°C.

Evolution of C02 began almost

immediately and continued for nearly 90 minutes.

Heating and stirring

were maintained for 12 hours, then the reaction mixture was removed from
the hotplate and cooled.

To the cooled reaction mixture were added

100 mL of 5% HC1, and the solvent removed under vacuum.

To the dried
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residue were added 50 mL of 5% HC1 and the acidic solution was washed
3 times with 50 raL portions of CH2CL2.

The solvent was removed under

vacuum on the rotary evaporator, then 100 mL of distilled H2O were added
to the resultant oil, and this solution was basified with NaOH pellets
(pH = 11).

This was extracted with five 50 mL portions of CHCI3.

The

combined CHCI3 extracts were dried over K2CO3, filtered, and the solvent
removed under vacuum.

The crude yield of H was 2.621 g (10.6 mmol,

77.5% yield) as a viscous amber oil.

Final purification of H was

accomplished by column chromatography.

A 50 mm x 1000 mm chromatography

column was packed with a 70-260 micron silica gel, and eluted with a
80:19:1, cyclohexane, isopropanol and ammonia hydroxide solution.

The

melting point of the eluted product (2.29 g, 59.1% yield) as the HC1
salt was 126-128<JC.
Anal.

Ci5H22N02Cl*H20 (M.W. = 247.34):

Calcd. C, 59.69; H, 8.02; N, 4.64;
Found

C, 59.93; H, 8.49; N, 4.41.

Mass Spec, CI, M+l» 248.
See IR Fig. 6 and NMR Fig. 7.
3-Dimethvlamino-7-hvdroxv-2.2-dimethvl-l-tetralone (I).

In a 25 mL

round bottom flask under a N2 atmosphere, 0.300 g (1.14 mmol) of t was
added to 7.00 mL of 55% HBr and the resultant solution was refluxed for
5 hours, at which time all starting material, as monitored by TLC, was
gone.

The reaction mixture was allowed to cool and maintained under a

steady flow of N2.

At this point, some crystals of the HBr salt of I

(63 mg, 19.3% yield) were filtered off. To the filtrate were added 3 mL
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of distilled H2O (pH of the solution was approximately 3).

The solution

was warmed to 50°C, 0.5 g activated charcoal was added, and the solution
was filtered.

The filtrate was basified with concentrated NH4OH and

allowed to evaporate at ambient conditions. The crystals, which had
formed after 7 days, were isolated by filtration and dried to give 81 mg
(35% yield) of the zwitterionic form of compound I.

Total combined

yields of both products was 55%.
Anal.

^12^15^2 (M.W. * 205.26);

Calcd. C, 70.22; H, 7.37; N, 6.82;
Found

C, 69.96; H, 7.64; N, 6.60.

Mass Spec, CI, M+l - 206.
See IR Fig. 4 and NMR Fig. 5.
3-Diroethylamino-7-hvdroxy-2.2-dimethyl-l-tetralone HBr (J).

In an

atmosphere of N2, 1.8 g of H (7.18 mmol) were added to 2.5 g (14.4 mmol)
of 48% HBr, and the resultant mixture was refluxed for 48 hours. The
solution was cooled and the crystals which had formed were isolated by
filtration.

This gave 1.45 g (4.62 mmol, 64% yield) of J:HBr, mp

268-273°C. The product was taken up in distilled H2O, treated with
activated charcoal, filtered, and allowed to recrystallize under
standard room conditions.

This procedure gave 1.32 g (58% yield) of

J:H8r, mp = 271-274°C.
Anal.

C!4H2oN02Br (M.W, = 233.31):

Calcd. C, 53.53; H, 6.42; N, 4.46;
Found

C, 53.64; H, 6.22; N, 4.49.

Mass Spec, CI, M+l — 234.
See IR Fig. 9 and NMR Fig. 8.
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3-Diroethylamino-7-methoxv-2,2-dimethyItetralin (K). A mixture of
30.0 mL glacial acetic acid, 1.0 mL perchloric acid, 0.10 g of H
(0.404 mrnol) and 0.20 g 10% Pd/C were placed in a Parr hydrogenation
apparatus and heated to 40°C at 50 psi of H2.

After seventy-two hours

hydrogen uptake had ceased. The reaction was filtered to remove the
catalyst and the volume of the solvent was reduced iji vacuo. The solu
tion was basified with a saturated solution of NaHCOj and then extracted
with two 30 mL portions of CHCI3. The combined CHCI3 extracts were taken
to dryness under vacuum. The resulting oil was dissolved in 30 mL of
dry Et20, and saturated ethereal:HC1 solution was added until no further
crystals precipitated.

Recrystallization from a minimal amount of warm

EtOAc yielded 0.068 g (0.252 mrnol, 62%) of K:HCL; mp = 145-147°C.
Anal.

C15H23N0 (M.W. = 233.35);

Mass Spec, CI, M+l = 234.
See IR Fig. 10 and NMR Fig. 11.
3-Dimethvlamino-7-hydroxv-2.2-dimethvltetralin HBr (L).

Under a N2

atmosphere, 40 mg of K (0.17 mmol) were dissolved in 1.5 mL of 48% HBr
and heated at 102°C for 16 hours. The solvent was removed by mild heat
ing (35-40°C) and maintaining a steady flow of N2. To the resultant oil,
2 drops of H2O and 0.5 mL of EtOH were added.

After allowing the mixture

to cool for 90 minutes, 3 volumes of THF were added and then the resultant
solution was refrigerated for 48 hours. The cold mixture yielded 18 mg
(0.0599 mol; 48.3%) of L:HBr crystals by decantation; mp = 253-256°C.
Anal.

Ci4H2iN0 (M.W. = 219.32);

Mass Spec, CI, M+l = 220.
See IR Fig. 12 and NMR Fig. 13.
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3-Amino-2,2-dimethyl-7-methoxytetralin (G). Into a Parr
hydrogenation bottle were placed 100 mg of F (0.4560 mmol), 50 mL of
glacial acetic acid and 5 drops of perchloric acid.

The bottle was

flushed with argon and 250 mg of 10% Pd/C were added to the mixture.
This was placed on a Parr hydrogenator at 60 psi of H2» covered with a
heating jacket and warmed to 45°C.

After 100 hours of hydrogenation,

the reaction was stopped, allowed to cool to room temperature, and the
catalyst was removed by filtration.

The filtrate was evaporated under

vacuum until a thick viscous oil remained.

The oil was dissolved in

5 mL of H2O and basified to pH = 10-10.5 with concentrated NH4OH
solution and extracted with three successive 10 tnL portions of CHCI3.
The extracts were dried over Na2S04, filtered, and the solvent was
evaporated in vacuo to 1/3 of its original volume.

The solution was

allowed to stand at atmospheric conditions until crystals formed
(12-20 hours).

Once crystals had formed, they were isolated by filtra

tion and dried under vacuum to yield 19.0 mg (20% partial yield) of G»
mp = 120-122°C. The filtrate was evaporated to dryness under vacuum.
The material left in the flask was dissolved in 25 mL Et20 and carefully
acidified with ethereal:HC1 solution.

Once crystal formation ceased,

the solution was filtered and the solid obtained was dried to afford
G:HC1; 0.061 g (51,72% yield), mp = 213-215°C. Total yield of G and
G;HC1 = 71.72%.
Anal.

C13H19NO (M.W. = 205.29);

Mass Spec, CI, M+l = 206
See IR Fig. 14 and NMR Fig. 15.

RESULTS AND DISCUSSION
Chemistry

The synthesis of intermediate F did not proceed as readily as
anticipated.

The reductive amination of compound B to compound C

resulted in significantly lower yields than previously reported.

After

numerous syntheses of compound C, minor procedural changes were insti
tuted and the reaction was closely monitored by TLC observations.

An

average purified yield of 45% was obtained, but only with the most
assiduous effort.

Normally the crude yields ranged from 40-65%,

depending on the length of time the reaction was refluxed.
The only other synthetic step which caused any significant problem
was the hydrolysis of D and subsequent isolation of the amino acid E.
The rigors of isolation and purification of an amino acid can be a very
unique and difficult problem.

In this case, the isolation of E was

especially difficult because its precursor ester (D) had not previously
been isolated from the hydrogenation reaction mixture in the synthetic
sequence on which the production of compound F was based.

Consequently,

the hydrolysis reaction mixture contained impurities which interfered
with the isolation of the amino acid (E).

Any quantity that did form

was not a. significant amount, nor was it pure.

To overcome this

problem the amino ester (D) was isolated and purified by fractional
distillation, following the catalytic hydrogenation.

Further

purification was done by making the D:HC1 salt and recrystallizing.
When only one spot was detectable by TLC, the D:HC1 was then hydrolyzed
35
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in nearly quantitative yields (>90%).

The initial product (compound E)

isolated was relatively clean (by TLC). Further purification by
repetitive crystallization resulted in very fine needle-like crystals
which did not show a discernible difference in the melting point.
Cyclization of the amino acid (E) in polyphosphoric acid (PPA) yielded
crude F in fairly consistent yields of 80-90%.
In light of the fact that all of the compounds preceding F had been
previously synthesized in the Medicinal Chemistry Department at UOP,
their spectral data will not be discussed here.

Since compound F was a

common intermediate for the synthesis of all further compounds, it is
used as the point of reference regarding spectral interpretations.
In the IR of F (Fig. 2) the major absorbances seen are the amine
stretching at **3500 cm-^ and amine bending at **1580 cm

the aromatic

stretching region at **3030 cm-^ and in—plane skeletal vibrations at
1600 cm-^; and a relatively sharp but wide aliphatic stretching region
at -3000-2500 cm"1.

The expected carbonyl stretching absorption

appeared at -1690 cm'1, and the multiple bond stretching absorption due
to the gem methyl groups at -1385 cm-1.
The NMR of F (Fig. 3) cleanly exhibited all the expected
absorbances.

The gem methyl protons appeared at 0.9 and 1.7 ppm.

The

protons on C-4 (Structure VI) show as a double-doublet at 3.4 and 3.6
ppm.

In this spectrum, solvent peaks for CD3OD occurred at 3.5

(quintuplet) and 4.4 ppm (singlet).

Buried on the upfield side of the

tall singlet at 3.85 ppm, which are the methoxy protons, is the proton
alpha to the primary amine at 3.7 ppm.

The aromatic protons appeared at
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7.0-8,0 ppm. The integrations were in agreement with the above assign
ments.

Once isolated and purified, F was stored as the free base. Care

was taken to store F under a dry inert atmosphere, otherwise it would
begin to slowly decompose. It was necessary on several occasions to
fractionally redistill F to remove the breakdown material.

As would be

expected, the HC1 salt was a more stable form, although not readily
usable for certain reactions.
The demethylation of F to create compound I presented a major
stumbling block.

A contemporary method, elucidated by Kenner Rice (75)

in the conversion of codeine to morphine, was originally attempted with
seemingly no results.

Alternative methods were investigated, one such

being a reaction using methylsulfonic acid and methionine.

A very low

yield of 20-30% (of I) was obtained but proved invaluable as a TLC
reference for another large-scale attempt with BBr3.

Once again very

low yields were obtained (20-30%), but the product was identical to the
methionine-methylsulfonic acid reaction product as seen on TLC. This
was not a sufficient amount for pharmacological testing.

When the

classic 0-demethylation reaction of refluxing with concentrated HBr was
employed, exemplary results occurred.

Refluxing overnight under a

steady flow of N2 rendered an I:HBr product in 20% yield.

The mother

liquor was basified with concentrated NH4OH and allowed to evaporate
over the next 7 days, resulting an additional 35% of the zwitterionic
free base. The total yield was twice that produced by the previous
reactions. Compound I was originally isolated as the HBr salt, and
an unusually high melting point > 300°C.

Using a micro hot stage
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melting point apparatus, a melting point of 335-338<>C was observed.
The C, II and N analysis was done on the lower melting free base
(mp = 182-184°C).
values.

The analysis was within ± 0.4% of the calculated

Mass spectrometry was done on both the free base and HBr salt.

Both analyses gave M+l ion 206, MW = 205.26.
The IR spectrum of I (Fig. 4) exhibited all the peaks found in the
IR of F with the noticeable addition of a sharp downfield absorbance
"3400-3200 cm-l, which could be due to the phenolic moiety.

The NMR of

compound I (Fig. 5) was run in D2O, and the spectrum appeared very
similar to that of F, but the singlet at 3.8 ppm (-GCH3) was gone, as
expected.

The peak pattern in the aromatic region (7.0-8.0 ppm) was

changed but the integration remained the same.
The N-dimethylation of F was originally attempted by reductive
methylation using NaCNBH3 and H2CO.

This procedure afforded two

products, probably the monomethyl amine and the dimethyl amine. Since
the composition of the.products isolated from reaction was a mixture of
the secondary and tertiary alkyl amines, and the overall yield of all
products from the reductive amination was only "43%, the EschweilerClarke method for dimethylation of the primary amine (F) was successfully
employed with little difficulty until the workup procedure.

The

formaldehyde present was a contaminant that was tenacious to wash free
from the product in almost any solvent.
afford a pure product.

Even distillation did not

Column chromatography was employed for final

purification of compound H.

The column was packed with 350 g silica

gel (60-250 microns, [J. T. Baker]) and eluted with an 80:19:1
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cyclohexane, isopropanol, and concentrated ammonia solution. The
recovered H (2.0 g) was converted to the H:HC1 salt. The IR of H
(Fig. 6) showed a significant increase in absorbance for the amine
moiety at **3650 cra~l due to the dimethyl groups. These methyl groups
tend to shift that peak upfield.

All other major peaks were accounted

for as previously mentioned.
The NMR of H:HC1 in CD30D (Fig. 7), unexpectedly showed the
N-dimethyl groups as two small singlet humps, one at ~2.0 ppm and the
other at 2.6 ppm.

Two obvious differences in the NMR spectra of H as

compared to that of F are that: 1) the gem methyl group peaks appeared
as a single peak absorbing at 0.95 ppm, and 2) the 2 protons at C-4
(Structure VI) no longer appeared as a double-doublet, but as a singlet
at 3.2 ppm.:

It is possible that the solvent peak had some smaller peaks

buried in the bottom right and left of the peak.

Compound H was the

only product in which C, H and N analyses indicated a monohydrated
product.

The mass spectrum ion M+l equalled 248 (M.W. = 247.34).

The first attempt at O-demethylation of H to produce J was done
using BBrj in CHCL3. This experiment was the deciding point of whether
or not this reaction showed any merit for O-demethylation in this series
of aminotetralin compounds.

Again, as in the previously mentioned

procedure for converting F to I, the yield was unacceptably low (30-38%
crude product).

Analogous to what was done for I, compound H was placed

in a reacti-vial with 48% HBr, sealed under a dry atmosphere of nitrogen,
and refluxed for 16 hours.

The solution was reduced to half its volume

with a stream of dry nitrogen gas, then allowed to sit until crystal
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formation subsided.

The J:HBr crystals were isolated in a 58% yield

after two recrystallizations.

Unfortunately, the solubility of J:HBr is

only 2 mg/mL in D2O which is not an adequate concentration to take an
NMR on the XL-200; therefore this spectrum was graciously run by George
Grey at Varian Associates on their XL—400.

The NMR of J:HBr (Fig. 8)

was very similar to the NMR of H, and showed the gem methyl protons as a
doublet at 1.2 ppm, the amino methyl groups as a single hump at 2.6 ppm,
but the absorption due to the methoxy group at 3.6-3.8 ppm was lacking
as expected.

All of the other peaks were, observed at previously

mentioned frequencies.
at

The IR of J (Fig. 9) showed a weak absorbance

-3150 cm"1 for the phenolic group.

were noted.

No other significant changes

All major peaks were accounted for as previously mentioned.

The simple reduction of F to G (carbonyl to the methylene at C-l
[Scheme II]) was attempted early on in this synthesis.
at this reduction failed to give definitive results.
mixture always showed multiple spots on TLC.

Initial attempts

The reaction

Initially the reduction of

F was attempted by catalytic hydrogenation with little apparent success.
Liquid ammonia and sodium (or liquid ammonia and lithium) were tried,
as was the LAH-AlCl3-lemonine reaction, again yielding no definitive
products.

It was decided to circumvent G and attempt instead the

conversion of

H to K.

Compound H was catalytically hydrogenated to yield compound K.

The

free base was converted to the HC1 salt and crystallized in a yield of
62%.

The IR spectrum of K (Fig. 10) showed a weak absorbance at -1725

cm'1 (carbonyl group) indicating that the product was contaminated with
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starting material.

This impurity also appeared on the mass spectrum

as an M+l = 234+16.

After subsequent recrystallization, the hrMR of K

(Fig. 11) was run and the integration was accurate. The gem methyl
groups appeared as a pair of singlets at 1.1 ppm and 1.3 ppm.

The C-l

protons appeared as the multiplet peaks between -2.45 ppm and 2.75 ppm,
the furthest downfield being buried under the amino methyls at 2.8 ppm.
All other peaks were as shown on the preceding NMR spectrum of compound H.
Compound K was O-demethylated (as were F and H) using concentrated
HBr under an inert atmosphere.

After refluxing overnight the solution

was concentrated to a viscous oil under vacuum.

Water and EtOH were

used to solubilize the reaction products, then THF was added to force
the LrllBr out of solution.

Because the yield was so low (18 mg), no

recrystallization was attempted.
The IR of L (Fig. 12) clearly showed the absence of the carbonyl
group at -1725

car1.

The NMR of L:HBr (Fig. 13) showed no methoxy group

at 3.6 ppm as in the NMR of K.

The amino methyl groups appeared as two

singlets at -2.7 ppm and -2.9 ppm.

Other than these two deviations, the

NMR spectrum of L was nearly superimposable on that of compound K.
Compound G was synthesized by the long term catalytic hydrogenation
with a two-fold excess of 10% Pd/C in acetic acid (with 1% perchloric
acid) and heating the hydrogenation mixture to 40-50°C.
The IR of G:Base (Fig. 14) showed the primary amine at -3380 cnT1
and the other major absorbances seen in the IR spectrum of F (Fig. 2).
The carbonyl absorbance at -1780 cm"1 was gone, although a barely
distinguishable blip at -1780 cm"1 was apparent from a minor contaminant.
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The NMR of G:Base (Fig. 15) was run in CD3OD. The gem methyl
groups were observed at 0.9 ppm and 1.1 ppm (some minor impurities at
1.3 ppm). The next singlet at 2.6 ppm were the protons at C-l
(Structure VI).

The rest of the spectrum was the same as the other NMRs^
Pharmacology

Preliminary testing of the compounds was done primarily by F3tima
Matos in the Pharmacology Department at the University of the Pacific.
All compounds were tested for agonist and antagonist capacity using the
electrically—stimulated guinea pig ileum longitudinal muscle (in vitro)
preparation.
Male guinea pigs (400—600 g) were used to supply the ileum from
which the longitudinal muscle was stripped, as per the procedure
described by Kosterlitz et al, (75, 76).

In a very general overview,

the strip of longitudinal muscle was set up in a 5 mL isolated tissue
bath (37°C) between two platinum electrodes.

The bath contained a Krebs

bicarbonate buffer solution.
The muscle strip was connected to a transducer, and the isometric
contractions, induced by electrical stimulation, were recorded on a
Grass Model 7 polygraph.

After the ileum reached equilibrium, the

"compound" was added to the bath and left in contact with the tissue
until maximal effects had been reached or three minutes had passed.
The preparations were then washed until equilibrium contractions had
been regained, ranging anywhere from 30-60 minutes between doses.
Dose-response data were taken and linear regression analyses were done
on a Hewlett-Packard model 86B computer using Hewlett Packard HP-83/85
General Statistics Pac and Regression Analysis Pac.
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Agonist Experiments
Fig. 16 is a plot of percent inhibition of the electrically
stimulated contraction vs the concentration of "compounds" given in
micromolar.
Table 2.

The information is also presented in tabular form in

Generally this class of drugs (compounds) did not show a

significant degree of potency in comparison to normorphine (NM),.
They ranged from 1/40 to 1/1000 the potency of NM, generally averaging
approximately 1/700.

In comparison to EKC, they were an additional

10-fold less potent.

Although the compounds were weak agonists they

were (with the exception of I and G) still able to exhibit anywhere
between 60 and 85% inhibition, which is not significantly different
from the maximum effects of NM at 72% and EKC at 71%.

The most potent

of the seven compounds synthesized was J (3-dimethylamino-7-hydroxy2,2-dimethyl-l-tetralone).
It has been generally observed in opioid compounds that optimum
activity is achieved when the C-7 group (Structure VI) is converted from
a methoxy to a hydroxy group.

With the conversion of compound F to

compound I (Scheme II), nearly a 7-fold decrease in potency was seen in
addition to a corresponding decrease in maximal effect (inhibition).
This same phenomenon was seen in the O-demethylation of compound K to
compound L, although somewhat less significant, on the order of a 25%
decrease in potency coupled with a 32% decrease in maximal effects.

The

only compound that elicited the expected increase in response was J, the
increase in potency on the order of five-fold and approximately a 20%
greater maximal effect.
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Table 2
Activity of Various Substituted 3-Amino-2 t 2-dimethyltetralins
in the Guinea Pig Ileum Longitudinal Muscle Preparation
Calculated by Linear Regression

Compound

N

IC50
(uM)

Slope

r

% Maximum
Inhibition

F

22

77.37

54.08

0.90

71

I

20

578.03

37.14

0.78

29

H

24

75.35

50.41

0.82

68

J

46

4.20

32.07

0.64

85

G

9

217.33

53.23

0.92

45

K

30

54.55

57.09

0.78

75

L

29

69.81

27.74

0.53

57

NM

145

0.10

38.37

0.72

72

EKC

75

0.02

40.44

0.73

71

IC50 =

concentration for 50% inhibition of the maximum response
calculated from the regression line equation.

r = Correlation coefficient.
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Even though the maximal effect and potency varied in the phenolic
compounds, it is interesting that all of them exhibited similar slopes,
apparently different from their methoxy precursors.
Small alkyl substituents on the amino group generally elicit a
change in both potency and maximal effect, although when compound F was
dimethylated to compound H, negligible changes in either potency or
maximal effect were seen. In the alkylation of compound G to K, amino
substitution accounted for a 65% increase in maximal effect and a
compound with 4 times the potency.

Evaluating compound I with respect

to compound J, the dimethylation exhibited the most significant changes
seen in this series of compounds.

The maximal effect of J was nearly

185% greater than that of compound I, and over 150 times as potent.
In trying to determine the site of action of these "compounds,"
experiments were done where the compounds were challenged by an
antagonist (naloxone).

It has been shown that low concentrations of

naloxone, e.g., a 100-300 nanomolar dose, will preferentially inhibit mu
receptor mediated agonist activity.

In higher doses (500-1000 nanomolar),

inhibition of both mu and kappa receptor mediated agonist activity should
occur (78).

Incubation time in the antagonism experiments for the

naloxone challenge of J was 3 minutes and 5 to 10 minutes for the other
compounds.

The results of these experiments are shown in Table 3.

Since a low dose of naloxone inhibited virtually all of the agonist
activity of J, this would suggest that its effects are being modulated
through the mu receptor.

When all of the other compounds were tested

their agonist effects were only partially blocked by the naloxone
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Table

3

Agonist Capacity of Aminotetralin Derivatives
Blocked by a Naloxone Challange

Compound

N

Naloxone HC1
(nM)

% Blockade
By Naloxone

NM

8

176

90

J

10

176

80

EKC

7

704

97

I

5

704

52

F

8

704

30

H

8

704

29

G

3

704

0

K

9

704

14

L

8

704

38

62

challenge, at a dose large enough to antagonize both mu and kappa
receptor agonists.

The implications of this type of response cannot

be unequivocally stated based on only one type of assay method and
challenged by a single antagonist.
Antagonist Experiments
A limited number of experiments were done with moderate doses
(5-10 nanomolar) of the compounds to test for their ability to
antagonize normorphine and ethylketocyclazocine.

Compound F partially

blocked normorphine, the prototype mu (u) receptor agonist, but did not
antagonize ethylketocyclazocine, the prototype kappa (k) receptor
agonist.

In addition, compounds I, H, and J showed no antagonist

capacity on either mu or kappa receptors, at these doses.

CONCLUSION

A series of aminotetralin compounds were synthesized and shown to
have weak to moderate opioid activity.

It was demonstrated that for

specific mu-raediated agonist activity in 3-amino-2,2-dimethyltetralin
compounds, the amine must be alkylated, the C-7 group must be in the
phenolic form and there must be a carbonyl group at C-l, as in compound
J.

Any analogues which deviated from the above characteristics resulted

in compounds that appeared to exert a significant portion of their
agonist effects through kappa-opioid receptors and/or other undetermined
receptor sites.

Compound K (3—amino—2,2—dimethyl—7-methoxytetralin)

exhibited the second highest maximal effect and the second lowest IC50
in this series of compounds.

However, only 14% of its inhibitory effects

(agonist activity) could be attributed to the kappa receptor.

This

was determined by a 704 nanomolar challenge of naloxone* which in the
GPI assay was capable of antagonizing the effects of EKC by 97%.

The

importance of this observation is that the compound was able to exhibit
effects which were nearly analogous to those of NM or EKC, but by means
of another opioid or a non-opioid receptor.
potent compound.

Compound G was not a very

Its maximum effect was approximately 50% inhibition,

yet 100% of that effect was mediated through some receptor site other
than the opioid mu and kappa.

It appeared that the lack of a C-l

carbonyl group combined with a methyl ether at C-7 seemed to direct
away from the mu and kappa receptor sites.

The methyl ethers (F, H, G

and K) exhibited no measurable mu effects; however, they showed varying
63

64
percentages of kappa effects.

Nearly all of the^ r
y
ot these compounds had the

same slope when determining the IC*n
8 cne ic50.
at C-7 generally

increases

Th«
-i •
The phenolic group substituent

activity and potency.

The pharmacological

effects of compound J support this generalization.

Demethylation of the

methyl ethers to a phenolic group resulted in compounds with decreased
activity and potency (I and L).

This discrepancy was observed by Martin

C20) in in vivo studies on other aminotetralins.

Thorough binding

studies will be needed to establish the importance of this observation.
The diversity of pharmacological effects elicited by aminotetralln
compounds was discussed by Cannon (79), who illustrated the numerous
sites of action where they may be capable of binding,
There exists no assay that is able to predict all the effects
and liabilities of a compound in humans or in different animal models,
although many improved methods of testing pharmacologic agents have
been developed in the past decade.

The GPI assay which was used for

preliminary pharmacological testing of these compounds is a very
sensitive assay. The findings from the GPI must be augmented with
other in vitro and in vivo assays.

The capability now exists to

delineate better the site of action of opioids.

Selective receptor

blockade experiments and/or experiments using multiple antagonists (of
different known receptors) would readily contribute to a better
understanding of the specific receptors involved.
There are currently many theories on the type (nature) of the
opioid receptor(s).

The more commonly accepted idea basically states

that there are distinct multiple receptor sites.

The findings of this
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research project substantiate but also question this idea.

Based on the

nature of these ligands, that they are all small synthetic modifications
of 3-amino-2,2-dimethyltetralins with some type of oxygen substituent at
C-7, and that the molecular size doesn't vary greatly, it would be
reasonable to assume that they would all interact with the same receptor
site. This is not to suggest that they would all bind in the same
manner at the given receptor., just at the same receptor.

If this were

true then the experiments done with the naloxone challenge should have
been able to antagonize all of the effects of all the compounds. This
of course was not what was observed.

Because the location(s) of action

(of the compounds that were not antagonized by naloxone) was not
identified, it is not obvious whether the effects are from a subclass of
opioid receptor or another physiological/pharmacological receptor site*
If future studies demonstrate that the effects were opioid, then this
study suggests the nearly identical structure of the different
receptors. If it is determined that the resultant agonist effects
(those not blocked by naloxone) are from a non-opioid receptor, than
information pertaining to the "other receptor(s)" would be gained and
help explain some of the "side effects" caused by the direct action
(binding) of the drug.

Also if this second hypothesis is the case, than

in regard to the opioid receptor site it could be stated that the effect
of the compound is mediated by the position in which it bands within a
three-dimensional receptor site.
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